HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [unchecked revision] | [checked revision] |
No edit summary |
No edit summary |
||
| (201 intermediate revisions by 8 users not shown) | |||
| Line 1: | Line 1: | ||
Welcome! | |||
'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.''' | |||
*For assignments, please see the "Author" column below (highlighted blue). | |||
*If empty (no name is present), please volunteer to create content for that disease! | |||
*If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content. | |||
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | |||
*Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added. | |||
__TOC__ | |||
<br /> | |||
{| class="wikitable sortable" style="margin:auto" | |||
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big> | |||
|- | |- | ||
!Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | | | ||
====CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)==== | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
|- | |- | ||
| | |[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra | ||
| | |4/8/24 | ||
| ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Clonal cytopenias of undetermined significance|Clonal cytopenias of undetermined significance]]||Disease|| || || || || ||FQR|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
|Chronic | |[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease||PENDING|| || || || ||FQR|| || | ||
| || | |Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | ||
|Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | |||
|Complete | |||
|Date page was created | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease||PENDING | ||
| || | | || || || ||FQR|| || | ||
|Chronic Neutrophilic Leukemia (CNL) | |||
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally | |||
|Complete | |||
|Date page was created | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||PENDING | ||
| || | | || || || ||FQR|| || | ||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified | |||
|Chelsea D. Kramish; Daynna J.Wolff | |||
|complete/pending faculty review | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease||PENDING | ||
| || | | || || || ||FQR|| || | ||
|Polycythemia Vera (PV) | |||
|Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | |||
|Complete | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||PENDING | ||
| || | | || || || ||FQR|| || | ||
|Essential Thrombocythemia (ET) | |||
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | |||
|Complete | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease||PENDING | ||
| || | | || || || ||FQR|| || | ||
|Primary Myelofibrosis (PMF) | |||
|T. Niroshi Senaratne, UCLA | |||
|Complete | |||
|8/4/2020 before submission<br /> | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |PENDING | ||
| || | | || || || ||FQR|| || | ||
|Juvenile Myelomonocytic Leukemia (JMML) | |||
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki> | |||
Associate Director | Division of Molecular Pathology, Genetics and Genomics | |||
Duke University Health System Clinical Laboratories | |||
|PENDING importing content and reference formatting | |||
| | |||
|FQR has emailed SR several times, last 4/20/22 | |||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | |[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING | ||
| || | | || || || ||FQR|| || | ||
|Myeloproliferative Neoplasm (MPN), Unclassifiable | |||
|Thomas Lee, MD, PhD, University of California, Los Angeles | |||
|Complete | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease||PENDING | ||
| || | | || || || ||FQR|| || | ||
|Cutaneous Mastocytosis | |||
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD | |||
|Complete | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease||PENDING|| || || || ||FQR|| || | ||
| || | |Systemic Mastocytosis | ||
|Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University | |||
|Complete | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease||PENDING | ||
| || | | || || || ||FQR|| || | ||
|Mast Cell Sarcoma | |||
|Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL | |||
|Complete | |||
| | |||
| | |||
|- | |- | ||
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || || | |[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease||PENDING | ||
| || | | || || || ||FQR|| || | ||
|Myelodysplastic Syndrome (MDS) with Isolated del(5q) | |||
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG | |||
|Complete | |||
| | |||
| | |||
|- | |- | ||
|Myelodysplastic neoplasm | |[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease||PENDING | ||
| || | | || || || ||FQR|| || | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
|Myelodysplastic neoplasm with | |[[HAEM5:Myelodysplastic neoplasm with biallelic TP53 inactivation|Myelodysplastic neoplasm with biallelic TP53 inactivation]]||Disease||Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?)|| || || || ||FQR|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Myelodysplastic neoplasm with low blasts|Myelodysplastic neoplasm with low blasts]]||Disease|| || || || || ||FQR|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Myelodysplastic neoplasm, hypoplastic|Myelodysplastic neoplasm, hypoplastic]]||Disease|| || || || || ||FQR|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease||PENDING | ||
| || | | || || || ||FQR|| || | ||
|Myelodysplastic Syndrome (MDS) with Excess Blasts | |||
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | |||
|Complete | |||
| | |||
| | |||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | |[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING | ||
| || | | || || || ||FQR|| || | ||
|Refractory Cytopenia of Childhood | |||
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | |||
|Complete | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease||PENDING | ||
| || | | || || || ||FQR|| || | ||
|Refractory Cytopenia of Childhood | |||
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | |||
|Complete | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease||PENDING | ||
| || | | || || || ||FQR|| || | ||
|Chronic Myelomonocytic Leukemia (CMML) | |||
|Linsheng Zhang, MD, PhD | |||
|Complete | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease||PENDING | ||
| || | | || || || ||FQR|| || | ||
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative | |||
|Linsheng Zhang, MD, PhD | |||
|Complete | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease||PENDING | ||
| || | | || || || ||FQR|| || | ||
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) | |||
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine | |||
|Complete | |||
|Date page was created | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease||PENDING | ||
| || | | || || || ||FQR|| || | ||
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | |||
|Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia | |||
|Complete | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]] | ||
|Disease | |||
|(Rabail Aslam, MD) | |||
Shashi Shetty, Ph.D. | |||
|7/1/24 | |||
| | |||
|Pending | |||
| | |||
|Jennelle Hodge (JH)/ Malini Sathanoori (MS) | |||
| | |||
| | |||
|Acute Promyelocytic Leukemia (APL) with PML-RARA | |||
|Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D. | |||
|Complete | |||
|03/01/2021-MS (re-review) | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]] | ||
|Disease | |||
| | |Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | ||
|Myeloid | |9/22/24 | ||
| | |||
|Pending | |||
| | |||
|JH_MS | |||
| | |||
| | |||
|Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 | |||
|Christine Bryke, MD<br>Beth Israel Deaconess Medical Center, Boston, MA | |||
|Complete | |||
|04/26/2021-MS (re-review) | |||
| | |||
|- | |- | ||
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]] | |||
|Disease | |||
|Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | |||
|9/22/24 | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |||
| | | | ||
| | | | ||
|Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | |||
|Christine Bryke, MD <br> Beth Israel Deaconess Medical Center, Boston, MA | |||
|Complete | |||
|03/01/2021-MS (re-review) | |||
| | | | ||
|- | |||
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]] | |||
|Disease | |||
|Jennelle C. Hodge, PhD | |||
| | | | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |||
| | | | ||
| | | | ||
|Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214 | |||
|Jennelle C. Hodge, PhD, FACMG | |||
|Complete | |||
|02/24/2021-MS (re-review) | |||
| | | | ||
|- | |- | ||
|Acute | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]] | |||
|Disease | |Disease | ||
| | |Jennelle C. Hodge, PhD | ||
| | | | ||
| | | | ||
|Complete | |||
| | | | ||
|JH_MS | |||
| | | | ||
| | | | ||
|Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1 | |||
|Jennelle C. Hodge, PhD, FACMG | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Acute myeloid leukaemia with | |[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
| | |(Xinxiu Xu)(trainee) Malini Sathanoori, Ph.D. | ||
| | |4/15/25 | ||
| | | | ||
| | | | ||
| Line 135: | Line 393: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |||
|Acute Myeloid Leukemia (AML) with BCR-ABL1 | |||
|Kay Weng Choy MBBS, Monash Medical Centre | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Acute myeloid leukaemia with | |[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
| | |(Rabail Aslam, MD) | ||
Shashi Shetty, Ph.D. | |||
| | |7/1/24 | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | | | ||
|Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3 | |||
|Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D. | |||
|Complete | |||
|03/01/2021-MS (re-review) | |||
| | | | ||
|- | |- | ||
|Acute myeloid leukaemia with | |[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]] | ||
|Disease | |Disease | ||
|Gordana Raca MD PhD, | |||
|9/8/25 | |||
| | |||
|Pending | |||
| | | | ||
|JH_MS | |||
| | | | ||
| | | | ||
|Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM | |||
|Gordana Raca MD PhD, University of Southern California, Los Angeles | |||
|Complete | |||
| | |||
|Need permission for figure? Update WHO? | |||
|- | |||
|[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]] | |||
|Disease | |||
|Eric McGinnis, MD, Fatma Al-Bulushi (trannee) | |||
|12/20/23 | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | | | ||
| | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
|Acute myeloid leukaemia with | |[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 171: | Line 458: | ||
|JH_MS | |JH_MS | ||
| | | | ||
|emailed request on 7/16/24. No response as of 9/7/25. | |||
Prior author: Xinjie Xu, PhD, FACMG | |||
Open to new author | |||
|Acute Myeloid Leukemia (AML) with Mutated NPM1 | |||
|Xinjie Xu, PhD, FACMG | |||
|Complete | |||
| | | | ||
| | |Add WHO reference<br /> | ||
|- | |- | ||
|Acute myeloid leukaemia with | |[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]] | ||
|Disease | |Disease | ||
| | |(Xinxiu Xu)(trainee) Malini Sathanoori, Ph.D. | ||
|4/15/25 | |||
| | | | ||
| | | | ||
| | | | ||
|JH_MS | |||
| | | | ||
| | | | ||
|Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA | |||
|Paul Defazio, MSc, Monash Health | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Acute myeloid leukaemia | |[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 195: | Line 493: | ||
|JH_MS | |JH_MS | ||
| | | | ||
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | |||
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes | |||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Acute myeloid leukaemia with | |[[HAEM5:Acute myeloid leukaemia with other defined genetic alterations|Acute myeloid leukaemia with other defined genetic alterations]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 208: | Line 510: | ||
| | | | ||
| | | | ||
| | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
|Acute myeloid leukaemia with | |[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 219: | Line 525: | ||
|JH_MS | |JH_MS | ||
| | | | ||
|Prior author: Celeste Eno, PhD | |||
Open to new author | |||
|Acute Myeloid Leukemia (AML) with Minimal Differentiation | |||
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Acute myeloid leukaemia | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]] | |||
|Disease | |Disease | ||
| | |Jennelle C. Hodge, PhD | ||
| | | | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |||
| | | | ||
| | | | ||
|Acute Myeloid Leukemia (AML) without Maturation | |||
|Jennelle C. Hodge, PhD, FACMG | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Acute myeloid leukaemia with | |[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]] | ||
|Disease | |Disease | ||
| | |Jennelle C. Hodge, PhD | ||
| | | | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |||
| | | | ||
| | | | ||
|Acute Myeloid Leukemia (AML) with Maturation | |||
|Jennelle C. Hodge, PhD, FACMG | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Acute | |[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]] | ||
|Disease | |Disease | ||
| | |Ashwini Yenamandra PhD FACMG | ||
|5/1/24 | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |||
| | | | ||
| | | | ||
| | |Acute Basophilic Leukemia | ||
| | |Ashwini Yenamandra PhD FACMG | ||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Acute | |[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 267: | Line 607: | ||
|JH_MS | |JH_MS | ||
| | | | ||
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | |||
|Acute Myelomonocytic Leukemia | |||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Acute | |[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 279: | Line 623: | ||
|JH_MS | |JH_MS | ||
| | | | ||
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | |||
|Acute Monoblastic and Monocytic Leukemia | |||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Acute | |[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]] | ||
|Disease | |Disease | ||
| | |Ashwini Yenamandra PhD FACMG | ||
|5/1/24 | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |||
| | | | ||
| | | | ||
| | |Pure Erythroid Leukemia | ||
| | |Ashwini Yenamandra PhD FACMG | ||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Acute | |[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 303: | Line 655: | ||
|JH_MS | |JH_MS | ||
| | | | ||
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | |||
|Acute Megakaryoblastic Leukemia (AMKL) | |||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]] | ||
|Disease | |Disease | ||
| | |Yalda Naeini | ||
|6/11/24 | |||
| | |||
|Pending | |||
| | |||
|JH_MS | |||
| | | | ||
| | | | ||
|Myeloid Sarcoma | |||
|Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine | |||
|Complete | |||
| | |||
| | |||
|- | |||
|RESOLVE 4th edition AML-Related NON-WHO entities content | |||
|[[HAEM4:Acute Myeloid Leukemia (AML) with Mutated FLT3|Acute Myeloid Leukemia (AML) with Mutated FLT3]] + [[HAEM4:Acute Myeloid Leukemia (AML) with NUP214-ABL1|Acute Myeloid Leukemia (AML) with NUP214-ABL1]] + [[HAEM4:Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6|Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6]] | |||
|ISSUE- FIX | |||
Resolve Non-WHO entities | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]] | ||
|Disease | |Disease | ||
| | |(Rabail Aslam, MD) | ||
Shashi Shetty, Ph.D. | |||
|7/1/24 | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |||
| | |||
| | |||
|Therapy-Related Myeloid Neoplasms | |||
|Shawn A. Silver, DO, Shashi Shetty, Ph.D. | |||
|Complete | |||
| | |||
|Check reference format | |||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]] | |||
|Disease | |||
|Malini Sathanoori, Ph.D. | |||
|12/6/24 | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | | | ||
| | |Multiple pages including overview page ([[Myeloid Neoplasms with Germline Predisposition|Myeloid Neoplasms with Germline Predisposition - Compendium of Cancer Genome Aberrations (ccga.io)]]) and 6 disease pages ( [[HAEM4:Acute Myeloid Leukaemia with Germline CEBPA Mutation]], [[HAEM4:Myeloid Neoplasms with Germline DDX41 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline ETV6 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline GATA2 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline RUNX1 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline ANKRD26 Mutation]]) | ||
|See links from instructions on the 5th edition page | |||
|Complete | |||
|Most were re-reviewed by MS on 03/02/2021 | |||
|For page Acute Myeloid Leukaemia with Germline CEBPA Mutation - Note by MS of "Review completed, awaiting some clarification from JH - 07/04/2022" | |||
|- | |- | ||
| | |[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 351: | Line 755: | ||
|JH_MS | |JH_MS | ||
| | | | ||
|Prior author: | |||
Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | |||
|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome | |||
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | |||
|Complete (all three pages) | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | |FQR | ||
| | |||
| | | | ||
|Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement | |||
|Jay Alden, DO | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Myeloid | |[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
|FQR | |||
| | | | ||
| | | | ||
|Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement | |||
|Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Myeloid neoplasm | |[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
|FQR | |||
| | | | ||
| | | | ||
|Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement | |||
|Yanna Ding, MD PhD | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Myeloid | |[[HAEM5:Myeloid/lymphoid neoplasm with JAK2 rearrangement|Myeloid/lymphoid neoplasm with JAK2 rearrangement]] | ||
|Disease | |Disease | ||
|ISSUE- FIX | |||
Resolve Non-WHO entities | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|FQR | |||
| | | | ||
| | | | ||
|Myeloid/Lymphoid Neoplasms with PCM1-JAK2 + consider a non-WHO page Myeloid/Lymphoid Neoplasms with ETV6-JAK2 ([[HAEM4:Myeloid/Lymphoid Neoplasms with ETV6-JAK2|Myeloid/Lymphoid Neoplasms with ETV6-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)]]) + another non-WHO page Myeloid/Lymphoid Neoplasms with BCR-JAK2 ([[HAEM4:Myeloid/Lymphoid Neoplasms with BCR-JAK2|Myeloid/Lymphoid Neoplasms with BCR-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)]] ) - both non-WHO pages are authored by trainee Lauren Crowson-Hindman and Daynna Wolff | |||
|Jessica Snider, M.D. and Daynna J. Wolff, PhD + non-WHO pages by trainee Lauren Crowson-Hindman and Daynna Wolff | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Myeloid | |[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement|Myeloid/lymphoid neoplasm with FLT3 rearrangement]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|FQR | |||
| | | | ||
| | | | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]] | ||
|Disease | |Disease | ||
| | |Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | ||
|9/22/24 | |||
| | |||
|Pending | |||
| | | | ||
|FQR | |||
| | | | ||
| | | | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]] | |||
|Disease | |||
|Rolando Garcia | |||
|2/7/2025 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|FQR | |||
| | | | ||
| | | | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
|Mixed-phenotype acute leukaemia with | |[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
|Tracy Tucker, PhD, FCCMG | |Tracy Tucker, PhD, FCCMG | ||
|4/6/24 | |||
| | |||
|Pending | |||
| | |||
|JH_MS | |||
| | | | ||
| | | | ||
|Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 | |||
|Tracy Tucker, PhD, FCCMG | |||
|Complete | |||
| | | | ||
| | |||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]] | |||
|Disease | |||
|Tracy Tucker, PhD, FCCMG | |||
|4/6/24 | |||
| | |||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |||
|Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged | |||
|Tracy Tucker, PhD, FCCMG | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Acute leukaemia of ambiguous lineage with other defined genetic alterations | |[[HAEM5:Acute leukaemia of ambiguous lineage with other defined genetic alterations|Acute leukaemia of ambiguous lineage with other defined genetic alterations]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 447: | Line 935: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]] | |||
|Disease | |||
|(Rabail Aslam, MD) | |||
Shashi Shetty, Ph.D. | |||
|7/1/24 | |||
| | |||
|Pending | |||
| | |||
|JH_MS | |||
| | |||
| | |||
|Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified | |||
|Priyatharsini Nirmalanantham, MD and Shashi Shetty, PhD | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Mixed-phenotype acute leukaemia, | |[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 459: | Line 968: | ||
|JH_MS | |JH_MS | ||
| | | | ||
|emailed 5/1/24 | |||
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified | |||
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|Mixed-phenotype acute leukaemia, | |[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]] | ||
|Disease | |Disease | ||
| | |Daynna Wolff, PhD | ||
|5/9/24 | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |||
| | | | ||
| | | | ||
| | |Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types | ||
| | |Elicia Goodale, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | ||
|PENDING | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |[[HAEM5:Acute leukaemia of ambiguous lineage, NOS|Acute leukaemia of ambiguous lineage, NOS]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]] | |||
|Disease | |||
|(Rabail Aslam, MD) | |||
Shashi Shetty, Ph.D. | |||
|7/1/24 | |||
| | |||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | | | ||
|Acute Undifferentiated Leukemia | |||
|Amelia Nakanishi, MD and Shashi Shetty, PhD | |||
|Complete | |||
| | | | ||
|Check reference format | |||
|- | |- | ||
| | | | ||
====CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)==== | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
|- | |- | ||
| | |[[HAEM5:Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|Greg Corboy (GC) | |||
| | | | ||
| | | | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]] | ||
|Disease | |Disease | ||
|Daynna Wolff | |||
|5/3/2025 | |||
|8/3/2025 | |||
|Pending | |||
| | | | ||
|GC | |||
| | |||
| | |||
|Blastic Plasmacytoid Dendritic Cell Neoplasm | |||
|Hao Liu, MD and Daynna J. Wolff, PhD | |||
|Complete | |||
| | |||
|Previously within myeloid section under JH/MS editors | |||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]] | |||
|Disease | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|GC | |||
| | | | ||
| | | | ||
|Langerhans Cell Histiocytosis | |||
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | |||
|Complete | |||
|5/19/2022 Emailed 5/6/2025, no reply<br /> | |||
|Date completed by author: 04/28/2022 | |||
|- | |- | ||
| | |[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|GC | |||
| | | | ||
| | | | ||
|Langerhans Cell Sarcoma | |||
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | |||
|Complete | |||
|5/19/2022 Emailed 5/6/2025, no reply<br /> | |||
|Date completed by author: 04/28/2022 | |||
|- | |- | ||
|[[HAEM5:Indeterminate dendritic cell tumour|Indeterminate dendritic cell tumour]] | |||
|Disease | |||
| | | | ||
| | | | ||
| Line 539: | Line 1,142: | ||
| | | | ||
| | | | ||
|GC | |||
| | | | ||
| | | | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]] | |||
|Disease | |||
|Muhammad Zulfiqar, MD | |||
|7/4/2025 | |||
|10/4/2025 | |||
|Pending | |||
| | | | ||
|GC | |||
| | | | ||
| | | | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]] | |||
|Disease | |||
|Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | |||
|9/22/24 | |||
|12/22/24 Emailed 9/4/2025 to remind | |||
|Pending | |||
| | | | ||
|GC | |||
| | |||
| | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]] | |||
|Disease | |||
|Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | |||
|9/22/24 | |||
|12/22/24 Emailed 9/4/2025 to remind | |||
|Pending | |||
| | | | ||
|GC | |||
| | | | ||
| | | | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]] | |||
|Disease | |||
|Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | |||
|9/22/24 | |||
|12/22/24 Emailed 9/4/2025 to remind | |||
|Pending | |||
| | | | ||
|GC | |||
| | | | ||
| | | | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:ALK-positive histiocytosis|ALK-positive histiocytosis]] | |||
|Disease | |||
| | | | ||
| | | | ||
| Line 557: | Line 1,222: | ||
| | | | ||
| | | | ||
|GC | |||
| | |||
| | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]] | |||
|Disease | |||
| | | | ||
| | | | ||
| Line 563: | Line 1,238: | ||
| | | | ||
| | | | ||
|GC | |||
| | | | ||
| | | | ||
|Histiocytic Sarcoma | |||
|Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic | |||
|Complete | |||
|10/01/2021 | |||
|Date completed by author: 10/01/2021. Emailed both authors 5/1/2025, no reply. | |||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
| | | | ||
====CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)==== | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
|- | |- | ||
|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]] | |||
|Disease | |||
|Muhammad Zulfiqar, MD | |||
|7/4/2025 | |||
|10/4/2025 Emailed 9/4/2025 to remind | |||
|Pending | |||
| | | | ||
|GC | |||
| | | | ||
| | | | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:IgG4-related disease|IgG4-related disease]] | |||
|Disease | |||
|Muhammad Zulfiqar, MD | |||
|7/4/2025 | |||
|10/4/2025 Emailed 9/4/2025 to remind | |||
|Pending | |||
| | | | ||
|GC | |||
| | |||
| | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:Unicentric Castleman disease|Unicentric Castleman disease]] | |||
|Disease | |||
| | | | ||
| | | | ||
| Line 591: | Line 1,333: | ||
| | | | ||
| | | | ||
|GC | |||
| | | | ||
| | | | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
|[[HAEM5:Idiopathic multicentric Castleman disease|Idiopathic multicentric Castleman disease]] | |||
|Disease | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|GC | |||
| | | | ||
| | | | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]] | |||
|Disease | |||
| | | | ||
| | | | ||
| Line 603: | Line 1,365: | ||
| | | | ||
| | | | ||
|GC | |||
| | | | ||
| | | | ||
|Multicentric Castleman Disease | |||
|Sudha Arumugam, MD | |||
|Complete | |||
|01/24/2022. Emailed 5/1/2025, no response | |||
|Date completed by author: 01/24/2022 | |||
|- | |- | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]] | |||
|Disease | |||
|PENDING | |||
| | |||
| | |||
| | |||
| | |||
|Holli Drendel (HD) | |||
| | |||
| | | | ||
|B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified | |||
|Holli Drendel | |||
|PENDING | |||
| | | | ||
| | | | ||
|- | |||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]] | |||
|Disease | |||
|PENDING | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|HD | |||
| | | | ||
| | | | ||
|B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy | |||
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG | |||
|PENDING | |||
| | | | ||
| | | | ||
|- | |- | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]] | |||
|Disease | |||
|PENDING | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|HD | |||
| | | | ||
| | | | ||
|B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy | |||
|Ashwini Yenamandra PhD FACMG Lisa Smith PhD FACMG Yassmine Akkari PhD FACMG | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]] | |||
|Disease | |||
|Holli Drendel | |||
| | | | ||
| | |||
|?Complete? Looks like tables need more editing. | |||
| | |||
|HD | |||
| | |||
| | |||
|B-Lymphoblastic Leukemia/Lymphoma with iAMP21 [but was completed as a 5th edition page by Holli] | |||
|Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte | |||
|?Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | |||
|Disease | |||
|PENDING | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|HD | |||
| | | | ||
| | |||
|B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 | |||
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG | |||
|PENDING | |||
| | |||
| | |||
|- | |||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]] | |||
|Disease | |||
|PENDING | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|HD | |||
| | |||
| | |||
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | |||
|Mark G. Evans, MD, University of California, Irvine Fabiola Quintero-Rivera, MD, University of California, Irvine | |||
|Complete | |||
| | | | ||
| | | | ||
|- | |- | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]] | |||
|Disease | |||
|PENDING | |||
| | |||
| | |||
| | | | ||
| | | | ||
|HD | |||
| | | | ||
| | |||
|B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged | |||
|Yassmine Akkari Nicolas Millan | |||
|PENDING | |||
| | |||
| | |||
|- | |||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]] | |||
|Disease | |||
|PENDING | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|HD | |||
| | | | ||
| | | | ||
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion | |||
|Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG Cancer Category/Type B-Lymphoblastic Leukemia/Lymphoma | |||
|PENDING | |||
| | | | ||
| | | | ||
|- | |- | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]] | |||
|Disease | |||
|Lei Zhang and Michelle Fan (trainee) | |||
|8/8/2024 | |||
| | | | ||
|Pending | |||
| | | | ||
|HD | |||
| | | | ||
| | | | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]] | |||
|Disease | |||
|PENDING | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|HD | |||
| | | | ||
| | |||
|B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1 | |||
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO | |||
|PENDING | |||
| | | | ||
| | | | ||
|- | |- | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]] | |||
|Disease | |||
|PENDING | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|HD | |||
| | | | ||
| | | | ||
|B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3 | |||
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO | |||
|PENDING | |||
| | | | ||
| | | | ||
|- | |||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]] | |||
|Disease | |||
|Aiko Otsubo | |||
|6/25/2024 | |||
| | |||
|Pending | |||
| | | | ||
|HD | |||
| | | | ||
| | | | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]] | ||
| | |Disease | ||
|Lei Zhang and Michelle Fan (trainee) | |||
|8/8/2024 | |||
| | |||
|Pending | |||
| | |||
|HD | |||
| | |||
| | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]] | ||
| | |Disease | ||
| | |||
| | |||
| | |||
| | |||
| | |||
|HD | |||
| | |||
| | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|RESOLVE 4th edition ALL-Related NON-WHO entities content | |||
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11) | |||
|ISSUE- FIX | |||
Resolve Non-WHO entities | |||
| | | | ||
| | | | ||
| Line 815: | Line 1,644: | ||
| | | | ||
| | | | ||
|ISSUE - FIX | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| || || || || || || || | |[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty | ||
| ||9/4/2025 sent E-mail reminder|| || ||Shivani Golem (SG) | |||
| || | | || | ||
|Monoclonal B-cell Lymphocytosis | |||
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty | |||
|PENDING, 4/30/2024 | |||
| | |||
|Assigned 12/19/2022 with completion date of 1/19/2023 | |||
|- | |- | ||
| || || || || || || || || | |[[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma|Chronic lymphocytic leukaemia/small lymphocytic lymphoma]]||Disease||Jaime Nagy, PhD, University of Iowa | ||
| || | |||
Renee Eigsti, MD, Pathology Services of Kalamazoo | |||
Honey Reddi, PhD, Belay Diagnostics | |||
| || ||Complete|| ||SG|| || | |||
|Already converted to 5th edition | |||
|Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD | |||
| | |||
| | |||
| | |||
|- | |- | ||
| || || || || || || || || | |[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||Michael Lack, MD, KUMC (trainee)/Shivani Golem | ||
| || | |7/16/24||9/4/2025 sent E-mail reminder||PENDING|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page. | ||
|Hairy Cell Leukemia | |||
|Snehal Patel, MD, PhD | |||
|Pending WHO 5th e. July 2024 | |||
| | |||
| | |||
|- | |- | ||
| || || || || || || || || | |[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||Madhu Pantrangi | ||
| || | |4/15/25|| ||9/4/2025 sent E-mail reminder|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page. | ||
|Splenic Marginal Zone Lymphoma | |||
|Snehal Patel, MD, PhD | |||
|Complete | |||
| | |||
| | |||
|- | |- | ||
| || || || || || || || || | |[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease|| | ||
| || | | || || || ||SG|| ||Need new author to update latest content. Prior author cannot update the page. | ||
|Splenic Diffuse Red Pulp Small B-cell Lymphoma | |||
|Snehal Patel, MD, PhD | |||
|Complete | |||
| | |||
| | |||
|- | |- | ||
| || || || || || || | | |[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]] | ||
|Disease | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|SG | |||
| | |||
|Need new author to update latest content. Prior author cannot update the page. | |||
|Hairy Cell Leukemia Variant | |||
|Snehal Patel, MD, PhD | |||
|Complete | |||
| | |||
| | |||
|- | |- | ||
| || || || || || || || | |[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]] | ||
|Disease | |||
| | |||
| | |||
|Sent e-mail to prev authors no reply | |||
| | |||
| | |||
|SG | |||
| | |||
|Email sent to request to update 2024 | |||
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia | |||
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) | |||
|Complete | |||
|4/12/2023 by FQR | |||
| | |||
|- | |- | ||
| || || || || || || || | |[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]] | ||
|Disease | |||
| | |||
| | |||
|Sent e-mail to prev authors no reply | |||
| | |||
| | |||
|SG | |||
| | |||
|Email sent to request to update 2024 | |||
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) | |||
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG* | |||
Department of Pathology and Laboratory Medicine and *Pediatrics, School of Medicine, University of California Irvine (UCI) | |||
|Complete | |||
|4/12/23 by FQR | |||
| | |||
|- | |- | ||
| || || || || || || || | |[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]] | ||
| | |Disease | ||
|Molly Walkenhorst | |||
| | |||
|9/4/2025 sent E-mail reminder | |||
| | |||
| | |||
|SG | |||
| | |||
| | |||
|NEW (No Prior) | |||
|Molly Walkenhorst, DO and Shivani Golem, PhD, FACMG | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| || || || || || || || | |[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]] | ||
|Disease | |||
|Andrew Ly | |||
| | |||
|9/4/2025 sent E-mail reminder | |||
| | |||
| | |||
|SG | |||
| | |||
| | |||
|Nodal Marginal Zone Lymphoma | |||
|Andrew Ly, DO and Shivani Golem, PhD, FACMG | |||
|Complete | |||
|5/28/2021 | |||
| | |||
|- | |- | ||
| || || || || || || || | |[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]] | ||
|Disease | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|SG | |||
| | |||
|Need new author to update latest content. Prior authors cannot update the page. | |||
|Paediatric Nodal Marginal Zone Lymphoma | |||
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD | |||
|Complete; Need new author to update latest content. Primary author cannot update the page. | |||
|11/11/2020 | |||
| | |||
|- | |- | ||
| || || || || || || | | |[[HAEM5:In situ follicular B-cell neoplasm|In situ follicular B-cell neoplasm]] | ||
|Disease | |||
|Rachel D. Burnside, PhD, MBA, FACMGG | |||
|7/28/2023 | |||
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | |||
|Pending | |||
| | |||
|SG | |||
| | |||
| | |||
|In Situ Follicular Neoplasia | |||
|Rachel D. Burnside, PhD, MBA, FACMGG | |||
|Pending | |||
| | |||
| | |||
|- | |- | ||
| || || || || || || | | |[[HAEM5:Follicular lymphoma|Follicular lymphoma]] | ||
|Disease | |||
|Rachel D. Burnside, PhD, MBA, FACMGG | |||
|7/28/2023 | |||
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | |||
|Pending | |||
| | |||
|SG | |||
| | |||
|Author also needs to correlate with 4th edition disease "Testicular Follicular Lymphoma", which is no longer a separate entity | |||
|(1) Follicular Lymphoma + (2) Testicular Follicular Lymphoma | |||
|(1 and 2) Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital Rachel D. Burnside, PhD, MBA, FACMG, University of Florida | |||
|Pending | |||
| | |||
| | |||
|- | |- | ||
| || || || || || || || | |[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]] | ||
|Disease | |||
|Rachel D. Burnside, PhD, MBA, FACMGG | |||
| | |||
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | |||
| | |||
| | |||
|SG | |||
| | |||
|Need new author to update latest content. Prior authors cannot update the page. | |||
|Paediatric-Type Follicular Lymphoma | |||
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG | |||
|Complete; Need new author to update latest content. Primary author cannot update the page. | |||
|8/16/2020 | |||
| | |||
|- | |- | ||
| || || || || || || | | |[[HAEM5:Duodenal-type follicular lymphoma|Duodenal-type follicular lymphoma]] | ||
|Disease | |||
|Rachel D. Burnside, PhD, MBA, FACMGG | |||
|7/28/2023 | |||
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside no reply 7/17/ | |||
|Pending | |||
| | |||
|SG | |||
| | |||
| | |||
|Duodenal-Type Follicular Lymphoma | |||
|No prior content | |||
| | |||
| | |||
| | |||
|- | |- | ||
| || || || || || || || | |[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]] | ||
|Disease | |||
|Linlin Gao | |||
| | |||
|9/4/2025 Sent E-mail to remind | |||
| | |||
| | |||
|SG | |||
| | |||
| | |||
|Primary Cutaneous Follicle Centre Lymphoma | |||
|Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG | |||
|Complete | |||
|09/10/2022 | |||
| | |||
|- | |- | ||
| | | |[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]] | ||
| | |Disease | ||
| | | | ||
| | |||
| | |||
| | | | ||
| | |||
| | |SG | ||
| | | | ||
| | |||
| | |In Situ Mantle Cell Neoplasia | ||
| | |Rina Kansal, MD; Versiti Blood Center of Wisconsin | ||
| | |Complete | ||
|7/26/2022 | |||
| | |||
| | |||
|- | |- | ||
|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]] | |||
|Disease | |||
|PENDING | |||
| | | | ||
|9/4/2025 set E-mail reminder | |||
| | | | ||
| | | | ||
|SG | |||
| | | | ||
| | | | ||
|Mantle Cell Lymphoma | |||
|Mahsa Khanlari, MD and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas | |||
|Pending | |||
| | | | ||
|Target completion date 8/15/20 | |||
|- | |||
|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]] | |||
|Disease | |||
|Farhan Sami | |||
| | | | ||
|9/4/2025 sent E-mail reminder | |||
| | | | ||
| | | | ||
|SG | |||
| | | | ||
| | | | ||
|NEW (No Prior) | |||
|Farhan Sami, MD and Shivani Golem, PhD, FACMG | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]] | |||
|Disease | |||
|Farhan Sami | |||
| | | | ||
|9/4/2025 sent E-mail reminder | |||
| | | | ||
| | | | ||
|SG | |||
| | | | ||
|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation | |||
|NEW (No Prior) | |||
|Farhan Sami, MD and Shivani Golem, PhD, FACMG | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| | |||
| || || || ||GC|| || | |||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified | |||
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | |||
|Pending | |||
| | | | ||
|Requested to update 14022022 | |||
|- | |||
|[[HAEM5:T-cell/histiocyte-rich large B-cell lymphoma|T-cell/histiocyte-rich large B-cell lymphoma]]||Disease|| || || || || ||GC|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland | |||
|5/6/2025||8/6/2025 Emailed 9/4/2025 to remind|| || ||GC|| || | |||
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | |||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland | |||
|Complete | |||
|24/02/2022 | |||
| | | | ||
|- | |||
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| | |||
| || || || ||GC|| || | |||
|ALK-Positive Large B-cell Lymphoma | |||
|Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | |||
| | | | ||
| | | | ||
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | |||
|- | |||
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| | |||
| || || || ||GC|| || | |||
|Large B-cell Lymphoma with IRF4 Rearrangement | |||
|Afia Hasnain, MBBS, PhD | |||
|Complete | |||
|5/26/2021. Emailed 5/7//2025, no reply | |||
| | | | ||
| | |- | ||
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| | |||
| || || || ||GC|| || | |||
|Burkitt-Like Lymphoma with 11q Aberration | |||
|Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | |||
|Complete | |||
|27/01/2022 Emailed 5/7//2025, no reply | |||
| | | | ||
|- | |- | ||
| || || || || || || || || | |[[HAEM5:Lymphomatoid granulomatosis|Lymphomatoid granulomatosis]]||Disease|| || || || || ||GC|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| || || || || || || || || | |[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee) + Andrew Siref as mentor | ||
| || | |3/22/24|| ||Pending|| ||GC|| || | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Diffuse large B-cell lymphoma associated with chronic inflammation|Diffuse large B-cell lymphoma associated with chronic inflammation]]||Disease|| || || || || ||GC|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | |[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| | ||
| || | | || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam | ||
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Fluid overload-associated large B-cell lymphoma|Fluid overload-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| | ||
| || | | || || || ||GC|| || | ||
|Plasmablastic Lymphoma | |||
|Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | |||
|Complete | |||
|28/03/2022 | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | ||
| || | |6/28/2025 | ||
|9/28/2025 Emailed 9/4/2025 to remind.|| || ||GC|| || | |||
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | |||
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | |||
|(1) Pending + (2) Complete | |||
|(1) Not ready + (2) 03/28/22 | |||
|For "Diffuse Large B-cell Lymphoma, Not Otherwise Specified" page from Ash, Greg requested to update 14022022 | |||
|- | |- | ||
| | |[[HAEM5:Primary cutaneous diffuse large B-cell lymphoma, leg type|Primary cutaneous diffuse large B-cell lymphoma, leg type]]||Disease|| || || || || ||GC|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland | ||
| || | |5/6/2025 | ||
|8/6/2025 Emailed 9/4/2025 to remind | |||
| || ||GC|| || | |||
|Intravascular Large B-cell Lymphoma | |||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | |||
|Complete | |||
|9/1/22 | |||
|Emailed 28/3/2022 for progress update | |||
|- | |- | ||
|Primary | |[[HAEM5:Primary mediastinal large B-cell lymphoma|Primary mediastinal large B-cell lymphoma]]||Disease|| || || || || ||GC|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Mediastinal grey zone lymphoma|Mediastinal grey zone lymphoma]]||Disease|| || || || || ||GC|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| | ||
| || | | || || || ||GC|| || | ||
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | |||
|Aiko Otsubo, PhD, Indiana University, Holli Drendel | |||
|Complete | |||
|16/11/2021 Emailed 5/6/2025, no reply | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease|| | ||
| || | | || || || ||GC|| || | ||
|Burkitt Lymphoma | |||
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland | |||
|Complete | |||
|28/06/2021 Emailed 5/6/2025, no reply | |||
| | |||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | |[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:KSHV/HHV8-positive diffuse large B-cell lymphoma|KSHV/HHV8-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:KSHV/HHV8-positive germinotropic lymphoproliferative disorder|KSHV/HHV8-positive germinotropic lymphoproliferative disorder]]||Disease|| || || || || ||GC|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Hyperplasias arising in immune deficiency/dysregulation|Hyperplasias arising in immune deficiency/dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content. What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page.|| || || || ||GC|| || | ||
| || | | | ||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]]. | ||
| || | Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)" | ||
| || || || ||GC|| || | |||
|Polymorphic Post-Transplant Lymphoproliferative Disorders | |||
|Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI) | |||
|Completed | |||
|26/4/2022 | |||
| | |||
|- | |- | ||
| | |[[HAEM5:EBV-positive mucocutaneous ulcer|EBV-positive mucocutaneous ulcer]]||Disease|| || || || || ||GC|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Lymphomas arising in immune deficiency / dysregulation|Lymphomas arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| || | ||
| || | | | ||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Inborn error of immunity-associated lymphoid proliferations and lymphomas|Inborn error of immunity-associated lymphoid proliferations and lymphomas]]||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5.|| || || || ||GC|| || | ||
| || | | | ||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||Xiaolin Hu | ||
| || | |5/7/2025 | ||
|8/7/2025 Reminder email sent 9/4/2025|| || | |||
|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | |||
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | |||
|(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez | |||
|Pending + Completed (03/21/22) | |||
|Not completed for checking (1, 3 and 4) + 03/21/22 (2) | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease||Muhammad Zulfiqar, MD | ||
| || | |7/4/2025 | ||
|10/4/2025 Reminder email sent 9/4/2025||Pending|| ||GC|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | |[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]] | ||
| | |Disease | ||
| | |||
| | |||
| | |||
| | |||
| | |||
|SG | |||
| | |||
| | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:IgM monoclonal gammopathy of undetermined significance|IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Non-IgM monoclonal gammopathy of undetermined significance|Non-IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Monoclonal gammopathy of renal significance|Monoclonal gammopathy of renal significance]]||Disease|| || || || || ||SG | ||
| || | | || | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease|| | ||
| || || || ||SG | |||
| || | | || | ||
|Primary Amyloidosis | |||
|Heather E. Williams, PhD, MS, PgD, ErCLG | |||
|?PENDING<br /> | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease|| | ||
| || || || ||SG | |||
| || | | || | ||
|Light Chain and Heavy Chain Deposition Disease | |||
|Chen Yang, MD, PhD, University of Michigan | |||
|Complete | |||
|10/15/2022 | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Mu heavy chain disease|Mu heavy chain disease]]||Disease|| || || || || ||SG | ||
| || | | || | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease|| | ||
| || || || ||SG | |||
| || | | || | ||
|Gamma Heavy Chain Disease | |||
|Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA | |||
|Complete | |||
|5/26/2021 | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Alpha heavy chain disease|Alpha heavy chain disease]]||Disease|| || || || || ||SG | ||
| || | | || | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease|| | ||
| || | | || || || | ||
|SG | |||
| ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga) | |||
|NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | |[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo and Zhenya Tang | ||
| || | |4/14/25||7/14/25 | ||
9/4/2025 Sent E-mail reminder to Dr. Tang | |||
|Pending|| ||SG | |||
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | |||
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | |||
|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG | |||
|Pending | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING | ||
| ||9/4/2025 E-mail sent to Dr. Senaratne | |||
| || | | || | ||
|SG | |||
| ||Note: author needs to include POEMS, TEMPI, and look for AESOP content | |||
|(1) POEMS Syndrome + (2) TEMPI Syndrome | |||
|(1 and 2) Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD | |||
|?PENDING | |||
| | |||
| | |||
|- | |- | ||
|Disease (5th Edition) | |||
| | |Page Type | ||
|Author (5th Edition) (Note: please indicate trainees in parenthesis) | |||
|Date Assigned to Author (5th Edition) | |||
|Target Completion Date (5th Edition) | |||
|Content Status (5th Edition) (Pending or Complete) | |||
|Date Completed by Author (5th Edition) | |||
|Associate Editor | |||
|Date of Last Editor Review (5th Edition) | |||
|Notes (5th Edition) | |||
|Correlated Prior Disease Name (4th Edition) | |||
|Correlated Prior Author (4th Edition) | |||
|Prior Content Status (4th Edition) (Pending or Complete) | |||
|Prior Date of Last Editor Review (4th Edition) | |||
|Prior Notes (4th Edition) | |||
|- | |- | ||
| | | | ||
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)==== | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
|- | |- | ||
| | |[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| || || || || ||Sumi Kitahara (SK) | ||
| || | | || | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee), Karin Miller, MD | ||
| || | |3/25/2024 | ||
| || || ||SK|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Indolent T-lymphoblastic proliferation|Indolent T-lymphoblastic proliferation]]||Disease|| || || || || ||SK|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]] | ||
|Disease | |||
|Fei Yang, MD | |||
| | |||
| | |||
|Pending | |||
| | |||
|SK | |||
| | |||
| | |||
|Early T-Cell Precursor Lymphoblastic Leukemia | |||
|Fei Yang, MD, FACMG, Kaiser Permanente Northwest | |||
|Pending | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]] | ||
| | |Disease | ||
|Parastou Tizro, MD (trainee); Celeste Eno, PhD | |||
|3/17/2024 | |||
| | |||
|Complete | |||
|6/24/2024 | |||
|SK | |||
|7/1/2024 | |||
| | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | |[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee); Michelle Don, MD, MS | ||
| || | |3/17/2024 (trainee name added on 9/9/24 by JH) | ||
|6/30/24 | |||
|Pending | |||
| ||SK|| || | |||
|T-cell Large Granular Lymphocytic Leukemia | |||
|Michelle Don, MD, MS | |||
|Pending | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee); | ||
| || | Michelle Don, MD, MS | ||
|3/17/2024 | |||
|6/30/24 | |||
|Pending | |||
| ||SK|| || | |||
|Chronic Lymphoproliferative Disorder of NK Cells | |||
|Michelle Don, MD | |||
|Pending | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease|| | ||
| || | | || || || ||SK|| || | ||
|Adult T-cell Leukemia/Lymphoma | |||
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | |||
|?Pending | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD | ||
| || | |3/22/2024 | ||
| || || ||SK|| || | |||
|Sézary Syndrome | |||
|Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | |||
|Pending | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD | ||
| || | |7/1/2024||8/31/2024 | ||
|Pending | |||
| ||SK|| || | |||
|Aggressive NK-cell Leukemia | |||
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD | |||
|?Pending | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc, Teodora Popa (resident) | ||
| || | |3/19/2024 | ||
| ||Pending | |||
| ||SK|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee), | ||
| || | |||
Andrew Siref, MD | |||
|4/12/2024 | |||
| ||Pending | |||
| ||SK|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD | ||
| || | |3/22/2024 | ||
| || || ||SK|| || | |||
|Mycosis Fungoides | |||
|Jane Scribner, MD and Daynna J. Wolff, PhD | |||
|Pending | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD | ||
| || | |7/1/2024 | ||
|8/31/224 | |||
|Pending | |||
| ||SK|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD | ||
| || | |7/1/2024||8/31/2024 | ||
|Pending | |||
| ||SK|| || | |||
|Primary Cutaneous Anaplastic Large Cell Lymphoma | |||
|Theresa Spivey, MD, Shashirekha Shetty, PhD | |||
|Pending | |||
| | |||
| | |||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | |[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee) | ||
| || | |3/19/2024 | ||
| ||Pending | |||
| ||SK|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD | ||
| || | |6/30/2024 | ||
| ||Pending | |||
| ||SK|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee), | ||
| || | |||
Andrew Siref, MD | |||
|4/12/2024|| ||Pending | |||
| ||SK|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Primary cutaneous peripheral T-cell lymphoma, NOS|Primary cutaneous peripheral T-cell lymphoma, NOS]]||Disease|| || || || || ||SK|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease|| | ||
| || | | || || || ||SK|| || | ||
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract | |||
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | |||
|Pending | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), | ||
| || | Andrew Siref, MD | ||
|3/20/2024 | |||
| ||Pending|| ||SK|| || | |||
|Enteropathy-Associated T-cell Lymphoma | |||
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD | |||
|Complete | |||
|1/21/2021 | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), | ||
| || | Andrew Siref, MD | ||
|3/20/2024 | |||
| ||Pending|| ||SK|| || | |||
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | |||
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | |||
|Pending | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease|| | ||
| || | | || || || ||SK|| || | ||
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) | |||
|Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) | |||
|Complete | |||
|9/26/2022 | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee); | ||
| || | Michelle Don, MD, MS | ||
|3/19/2024 | |||
|6/30/24 | |||
|Complete | |||
|5/13/24||SK||10/18/24|| | |||
|Hepatosplenic T-cell Lymphoma | |||
|Michelle Don, MD, MS | |||
|Complete | |||
|1/21/2021 | |||
| | |||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | |[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee) | ||
| || | |||
Sumire Kitahara, MD | |||
|6/6/24|| ||Pending | |||
| ||SK|| || | |||
|Anaplastic Large Cell Lymphoma, ALK-Positive | |||
|Miguel Gonzalez Mancera, MD | |||
Sumire Kitahara, MD | |||
Cedars-Sinai, Los Angeles, CA | |||
|Complete | |||
|09/23/2022 | |||
| | |||
|- | |- | ||
| | |[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee) | ||
| || | Sumire Kitahara, MD | ||
|6/6/24|| ||Pending | |||
| ||SK|| || | |||
|Anaplastic Large Cell Lymphoma, ALK-Negative | |||
|Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA | |||
|Complete | |||
|09/23/2022 | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD | ||
| || | |4/1/2024 | ||
| ||Pending|| ||SK|| || | |||
|Breast Implant-Associated Anaplastic Large Cell Lymphoma | |||
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | |||
|Pending | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | ||
| || | | ||Pending|| ||SK|| ||prior authors not available | ||
|Angioimmunoblastic T-cell Lymphoma | |||
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG | |||
|Pending | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | ||
| || | | ||Pending|| ||SK|| || | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease|| | ||
| || | | || || || ||SK|| || | ||
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype | |||
|Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | |||
|Pending | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD | ||
| || | |6/25/2023 | ||
| || || ||SK|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), Andrew Siref, MD||3/22/2024|| ||Pending|| ||SK|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc, Teodora Popa (resident) | ||
| || | |3/19/2024 | ||
| ||Pending | |||
| ||SK|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Severe mosquito bite allergy|Severe mosquito bite allergy]]||Disease|| || || || || ||SK|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | |[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD | ||
| || | |3/25/2024 | ||
| || || ||SK|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD | ||
| || | |3/25/2024 | ||
| || || ||SK|| ||prior authors not available | |||
|Systemic EBV-Positive T-cell Lymphoma of Childhood | |||
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA | |||
|Complete | |||
|11/21/2021 | |||
| | |||
|- | |- | ||
| | | | ||
====CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)==== | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
|- | |- | ||
| | |[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]] | ||
|Disease | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|GC | |||
| | |||
| | |||
|Follicular Dendritic Cell Sarcoma | |||
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG | |||
|?Pending | |||
| | |||
| | |||
|- | |- | ||
| | |[[HAEM5:EBV-positive inflammatory follicular dendritic cell sarcoma|EBV-positive inflammatory follicular dendritic cell sarcoma]] | ||
| | |Disease | ||
| | |||
| | |||
| | |||
| | |||
| | |||
|GC | |||
| | |||
| | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Fibroblastic reticular cell tumour|Fibroblastic reticular cell tumour]] | ||
| | |Disease | ||
| | |||
| | |||
| | |||
| | |||
| | |||
|GC | |||
| | |||
| | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Intranodal palisaded myofibroblastoma|Intranodal palisaded myofibroblastoma]] | ||
| | |Disease | ||
| | |||
| | |||
| | |||
| | |||
| | |||
|GC | |||
| | |||
| | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | |[[HAEM5:Littoral cell angioma|Littoral cell angioma]] | ||
| | |Disease | ||
| | |||
| | |||
| | |||
| | |||
| | |||
|GC | |||
| | |||
| | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Splenic hamartoma|Splenic hamartoma]] | ||
| | |Disease | ||
| | |||
| | |||
| | |||
| | |||
| | |||
|GC | |||
| | |||
| | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Sclerosing angiomatoid nodular transformation (SANT) of spleen|Sclerosing angiomatoid nodular transformation (SANT) of spleen]] | ||
| | |Disease | ||
| | |||
| | |||
| | |||
| | |||
| | |||
|GC | |||
| | |||
| | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | | | ||
====CHAPTER 7 (GENETIC TUMOUR SYNDROMES)==== | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
| | |||
----<br /> | |||
|- | |- | ||
|Fanconi anaemia||Disease|| || || || || || | |[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | | |N/A||N/A | ||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
|Bloom syndrome||Disease|| || || || || || | |[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
|Ataxia-telangiectasia syndrome||Disease|| || || || || || | |[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]||N/A||N/A||N/A||N/A||N/A||N/A||N/A | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
|RASopathies||Disease|| || || || || ||NA|| | |[[HAEM5:RASopathies|RASopathies]]||Disease|| || || || || ||NA|| || | ||
| || | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|} | |} | ||
Latest revision as of 05:40, 9 September 2025
Welcome!
A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.
- For assignments, please see the "Author" column below (highlighted blue).
- If empty (no name is present), please volunteer to create content for that disease!
- If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.
- To volunteer, please [Contact us] with your page of interest.
- Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Clonal haematopoiesis | Disease | Meenakshi Mehrotra | 4/8/24 | Pending | Fabiola Quintero-Rivera (FQR) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
| Clonal cytopenias of undetermined significance | Disease | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Chronic myeloid leukaemia | Disease | PENDING | FQR | Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | Complete | Date page was created | |||||||
| Chronic neutrophilic leukaemia | Disease | PENDING | FQR | Chronic Neutrophilic Leukemia (CNL) | Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine **contributed equally | Complete | Date page was created | |||||||
| Chronic eosinophilic leukaemia | Disease | PENDING | FQR | Chronic Eosinophilic Leukemia, Not Otherwise Specified | Chelsea D. Kramish; Daynna J.Wolff | complete/pending faculty review | ||||||||
| Polycythaemia vera | Disease | PENDING | FQR | Polycythemia Vera (PV) | Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | Complete | ||||||||
| Essential thrombocythaemia | Disease | PENDING | FQR | Essential Thrombocythemia (ET) | Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | Complete | ||||||||
| Primary myelofibrosis | Disease | PENDING | FQR | Primary Myelofibrosis (PMF) | T. Niroshi Senaratne, UCLA | Complete | 8/4/2020 before submission |
|||||||
| Juvenile myelomonocytic leukaemia | Disease | PENDING | FQR | Juvenile Myelomonocytic Leukemia (JMML) | Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology
Associate Director | Division of Molecular Pathology, Genetics and Genomics Duke University Health System Clinical Laboratories |
PENDING importing content and reference formatting | FQR has emailed SR several times, last 4/20/22 | |||||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| Myeloproliferative neoplasm, NOS | Disease | PENDING | FQR | Myeloproliferative Neoplasm (MPN), Unclassifiable | Thomas Lee, MD, PhD, University of California, Los Angeles | Complete | ||||||||
| Cutaneous mastocytosis | Disease | PENDING | FQR | Cutaneous Mastocytosis | S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD | Complete | ||||||||
| Systemic mastocytosis | Disease | PENDING | FQR | Systemic Mastocytosis | Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University | Complete | ||||||||
| Mast cell sarcoma | Disease | PENDING | FQR | Mast Cell Sarcoma | Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL | Complete | ||||||||
| Myelodysplastic neoplasm with low blasts and 5q deletion | Disease | PENDING | FQR | Myelodysplastic Syndrome (MDS) with Isolated del(5q) | Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG | Complete | ||||||||
| Myelodysplastic neoplasm with low blasts and SF3B1 mutation | Disease | PENDING | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||||
| Myelodysplastic neoplasm with biallelic TP53 inactivation | Disease | Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?) | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||||
| Myelodysplastic neoplasm with low blasts | Disease | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Myelodysplastic neoplasm, hypoplastic | Disease | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Myelodysplastic neoplasm with increased blasts | Disease | PENDING | FQR | Myelodysplastic Syndrome (MDS) with Excess Blasts | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | Complete | ||||||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| Childhood myelodysplastic neoplasm with low blasts | Disease | PENDING | FQR | Refractory Cytopenia of Childhood | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | Complete | ||||||||
| Childhood myelodysplastic neoplasm with increased blasts | Disease | PENDING | FQR | Refractory Cytopenia of Childhood | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | Complete | ||||||||
| Chronic myelomonocytic leukaemia | Disease | PENDING | FQR | Chronic Myelomonocytic Leukemia (CMML) | Linsheng Zhang, MD, PhD | Complete | ||||||||
| Myelodysplastic/myeloproliferative neoplasm with neutrophilia | Disease | PENDING | FQR | Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative | Linsheng Zhang, MD, PhD | Complete | ||||||||
| Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis | Disease | PENDING | FQR | Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) | Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine | Complete | Date page was created | |||||||
| Myelodysplastic/myeloproliferative neoplasm, NOS | Disease | PENDING | FQR | Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia | Complete | ||||||||
| Acute promyelocytic leukaemia with PML::RARA fusion | Disease | (Rabail Aslam, MD)
Shashi Shetty, Ph.D. |
7/1/24 | Pending | Jennelle Hodge (JH)/ Malini Sathanoori (MS) | Acute Promyelocytic Leukemia (APL) with PML-RARA | Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D. | Complete | 03/01/2021-MS (re-review) | |||||
| Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion | Disease | Mayuri Shende (trainee) and Scott Turner (mentor) |
9/22/24 | Pending | JH_MS | Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 | Christine Bryke, MD Beth Israel Deaconess Medical Center, Boston, MA |
Complete | 04/26/2021-MS (re-review) | |||||
| Acute myeloid leukaemia with CBFB::MYH11 fusion | Disease | Mayuri Shende (trainee) and Scott Turner (mentor) |
9/22/24 | Pending | JH_MS | Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | Christine Bryke, MD Beth Israel Deaconess Medical Center, Boston, MA |
Complete | 03/01/2021-MS (re-review) | |||||
| Acute myeloid leukaemia with DEK::NUP214 fusion | Disease | Jennelle C. Hodge, PhD | Pending | JH_MS | Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214 | Jennelle C. Hodge, PhD, FACMG | Complete | 02/24/2021-MS (re-review) | ||||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| Acute myeloid leukaemia with RBM15::MRTFA fusion | Disease | Jennelle C. Hodge, PhD | Complete | JH_MS | Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1 | Jennelle C. Hodge, PhD, FACMG | Complete | |||||||
| Acute myeloid leukaemia with BCR::ABL1 fusion | Disease | (Xinxiu Xu)(trainee) Malini Sathanoori, Ph.D. | 4/15/25 | JH_MS | Acute Myeloid Leukemia (AML) with BCR-ABL1 | Kay Weng Choy MBBS, Monash Medical Centre | Complete | |||||||
| Acute myeloid leukaemia with KMT2A rearrangement | Disease | (Rabail Aslam, MD)
Shashi Shetty, Ph.D. |
7/1/24 | Pending | JH_MS | Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3 | Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D. | Complete | 03/01/2021-MS (re-review) | |||||
| Acute myeloid leukaemia with MECOM rearrangement | Disease | Gordana Raca MD PhD, | 9/8/25 | Pending | JH_MS | Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM | Gordana Raca MD PhD, University of Southern California, Los Angeles | Complete | Need permission for figure? Update WHO? | |||||
| Acute myeloid leukaemia with NUP98 rearrangement | Disease | Eric McGinnis, MD, Fatma Al-Bulushi (trannee) | 12/20/23 | Pending | JH_MS | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
| Acute myeloid leukaemia with NPM1 mutation | Disease | JH_MS | emailed request on 7/16/24. No response as of 9/7/25.
Prior author: Xinjie Xu, PhD, FACMG Open to new author |
Acute Myeloid Leukemia (AML) with Mutated NPM1 | Xinjie Xu, PhD, FACMG | Complete | Add WHO reference | |||||||
| Acute myeloid leukaemia with CEBPA mutation | Disease | (Xinxiu Xu)(trainee) Malini Sathanoori, Ph.D. | 4/15/25 | JH_MS | Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA | Paul Defazio, MSc, Monash Health | Complete | |||||||
| Acute myeloid leukaemia, myelodysplasia-related | Disease | JH_MS | emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes | Fei Yang, MD, FACMG Oregon Health & Science University |
Complete | ||||||||
| Acute myeloid leukaemia with other defined genetic alterations | Disease | JH_MS | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Acute myeloid leukaemia with minimal differentiation | Disease | JH_MS | Prior author: Celeste Eno, PhD
Open to new author |
Acute Myeloid Leukemia (AML) with Minimal Differentiation | Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine | Complete | ||||||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| Acute myeloid leukaemia without maturation | Disease | Jennelle C. Hodge, PhD | Pending | JH_MS | Acute Myeloid Leukemia (AML) without Maturation | Jennelle C. Hodge, PhD, FACMG | Complete | |||||||
| Acute myeloid leukaemia with maturation | Disease | Jennelle C. Hodge, PhD | Pending | JH_MS | Acute Myeloid Leukemia (AML) with Maturation | Jennelle C. Hodge, PhD, FACMG | Complete | |||||||
| Acute basophilic leukaemia | Disease | Ashwini Yenamandra PhD FACMG | 5/1/24 | Pending | JH_MS | Acute Basophilic Leukemia | Ashwini Yenamandra PhD FACMG | Complete | ||||||
| Acute myelomonocytic leukaemia | Disease | JH_MS | emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | Acute Myelomonocytic Leukemia | Fei Yang, MD, FACMG Oregon Health & Science University |
Complete | ||||||||
| Acute monocytic leukaemia | Disease | JH_MS | emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | Acute Monoblastic and Monocytic Leukemia | Fei Yang, MD, FACMG Oregon Health & Science University |
Complete | ||||||||
| Acute erythroid leukaemia | Disease | Ashwini Yenamandra PhD FACMG | 5/1/24 | Pending | JH_MS | Pure Erythroid Leukemia | Ashwini Yenamandra PhD FACMG | Complete | ||||||
| Acute megakaryoblastic leukaemia | Disease | JH_MS | emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | Acute Megakaryoblastic Leukemia (AMKL) | Fei Yang, MD, FACMG Oregon Health & Science University |
Complete | ||||||||
| Myeloid sarcoma | Disease | Yalda Naeini | 6/11/24 | Pending | JH_MS | Myeloid Sarcoma | Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine | Complete | ||||||
| RESOLVE 4th edition AML-Related NON-WHO entities content | Acute Myeloid Leukemia (AML) with Mutated FLT3 + Acute Myeloid Leukemia (AML) with NUP214-ABL1 + Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6 | ISSUE- FIX
|
||||||||||||
| Myeloid neoplasm post cytotoxic therapy | Disease | (Rabail Aslam, MD)
Shashi Shetty, Ph.D. |
7/1/24 | Pending | JH_MS | Therapy-Related Myeloid Neoplasms | Shawn A. Silver, DO, Shashi Shetty, Ph.D. | Complete | Check reference format | |||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| Myeloid neoplasms associated with germline predisposition | Disease | Malini Sathanoori, Ph.D. | 12/6/24 | Pending | JH_MS | Multiple pages including overview page (Myeloid Neoplasms with Germline Predisposition - Compendium of Cancer Genome Aberrations (ccga.io)) and 6 disease pages ( HAEM4:Acute Myeloid Leukaemia with Germline CEBPA Mutation, HAEM4:Myeloid Neoplasms with Germline DDX41 Mutation, HAEM4:Myeloid Neoplasms with Germline ETV6 Mutation, HAEM4:Myeloid Neoplasms with Germline GATA2 Mutation, HAEM4:Myeloid Neoplasms with Germline RUNX1 Mutation, HAEM4:Myeloid Neoplasms with Germline ANKRD26 Mutation) | See links from instructions on the 5th edition page | Complete | Most were re-reviewed by MS on 03/02/2021 | For page Acute Myeloid Leukaemia with Germline CEBPA Mutation - Note by MS of "Review completed, awaiting some clarification from JH - 07/04/2022" | ||||
| Myeloid proliferations associated with Down syndrome | Disease | JH_MS | Prior author:
Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO |
MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome | Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | Complete (all three pages) | ||||||||
| Myeloid/lymphoid neoplasm with PDGFRA rearrangement | Disease | PENDING | FQR | Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement | Jay Alden, DO | Complete | ||||||||
| Myeloid/lymphoid neoplasm with PDGFRB rearrangement | Disease | PENDING | FQR | Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement | Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD | Complete | ||||||||
| Myeloid/lymphoid neoplasm with FGFR1 rearrangement | Disease | PENDING | FQR | Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement | Yanna Ding, MD PhD | Complete | ||||||||
| Myeloid/lymphoid neoplasm with JAK2 rearrangement | Disease | ISSUE- FIX
|
FQR | Myeloid/Lymphoid Neoplasms with PCM1-JAK2 + consider a non-WHO page Myeloid/Lymphoid Neoplasms with ETV6-JAK2 (Myeloid/Lymphoid Neoplasms with ETV6-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)) + another non-WHO page Myeloid/Lymphoid Neoplasms with BCR-JAK2 (Myeloid/Lymphoid Neoplasms with BCR-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io) ) - both non-WHO pages are authored by trainee Lauren Crowson-Hindman and Daynna Wolff | Jessica Snider, M.D. and Daynna J. Wolff, PhD + non-WHO pages by trainee Lauren Crowson-Hindman and Daynna Wolff | Complete | ||||||||
| Myeloid/lymphoid neoplasm with FLT3 rearrangement | Disease | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion | Disease | Mayuri Shende (trainee) and Scott Turner (mentor) |
9/22/24 | Pending | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
| Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes | Disease | Rolando Garcia | 2/7/2025 | Pending | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
| Mixed-phenotype acute leukaemia with BCR::ABL1 fusion | Disease | Tracy Tucker, PhD, FCCMG | 4/6/24 | Pending | JH_MS | Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 | Tracy Tucker, PhD, FCCMG | Complete | ||||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| Mixed-phenotype acute leukaemia with KMT2A rearrangement | Disease | Tracy Tucker, PhD, FCCMG | 4/6/24 | Pending | JH_MS | Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged | Tracy Tucker, PhD, FCCMG | Complete | ||||||
| Acute leukaemia of ambiguous lineage with other defined genetic alterations | Disease | JH_MS | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Mixed-phenotype acute leukaemia, B/myeloid | Disease | (Rabail Aslam, MD)
Shashi Shetty, Ph.D. |
7/1/24 | Pending | JH_MS | Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified | Priyatharsini Nirmalanantham, MD and Shashi Shetty, PhD | Complete | ||||||
| Mixed-phenotype acute leukaemia, T/myeloid | Disease | PENDING | JH_MS | emailed 5/1/24 | Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified | Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine | Complete | |||||||
| Mixed-phenotype acute leukaemia, rare types | Disease | Daynna Wolff, PhD | 5/9/24 | Pending | JH_MS | Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types | Elicia Goodale, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | PENDING | ||||||
| Acute leukaemia of ambiguous lineage, NOS | Disease | JH_MS | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Acute undifferentiated leukaemia | Disease | (Rabail Aslam, MD)
Shashi Shetty, Ph.D. |
7/1/24 | Pending | JH_MS | Acute Undifferentiated Leukemia | Amelia Nakanishi, MD and Shashi Shetty, PhD | Complete | Check reference format | |||||
CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm | Disease | Greg Corboy (GC) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Blastic plasmacytoid dendritic cell neoplasm | Disease | Daynna Wolff | 5/3/2025 | 8/3/2025 | Pending | GC | Blastic Plasmacytoid Dendritic Cell Neoplasm | Hao Liu, MD and Daynna J. Wolff, PhD | Complete | Previously within myeloid section under JH/MS editors | ||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| Langerhans cell histiocytosis | Disease | GC | Langerhans Cell Histiocytosis | Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | Complete | 5/19/2022 Emailed 5/6/2025, no reply |
Date completed by author: 04/28/2022 | |||||||
| Langerhans cell sarcoma | Disease | GC | Langerhans Cell Sarcoma | Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | Complete | 5/19/2022 Emailed 5/6/2025, no reply |
Date completed by author: 04/28/2022 | |||||||
| Indeterminate dendritic cell tumour | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Interdigitating dendritic cell sarcoma | Disease | Muhammad Zulfiqar, MD | 7/4/2025 | 10/4/2025 | Pending | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||
| Juvenile xanthogranuloma | Disease | Mayuri Shende (trainee) and Scott Turner (mentor) |
9/22/24 | 12/22/24 Emailed 9/4/2025 to remind | Pending | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||
| Erdheim-Chester disease | Disease | Mayuri Shende (trainee) and Scott Turner (mentor) |
9/22/24 | 12/22/24 Emailed 9/4/2025 to remind | Pending | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||
| Rosai-Dorfman Disease | Disease | Mayuri Shende (trainee) and Scott Turner (mentor) |
9/22/24 | 12/22/24 Emailed 9/4/2025 to remind | Pending | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||
| ALK-positive histiocytosis | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Histiocytic sarcoma | Disease | GC | Histiocytic Sarcoma | Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic | Complete | 10/01/2021 | Date completed by author: 10/01/2021. Emailed both authors 5/1/2025, no reply. | |||||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reactive B-cell rich lymphoid proliferations that can mimic lymphoma | Disease | Muhammad Zulfiqar, MD | 7/4/2025 | 10/4/2025 Emailed 9/4/2025 to remind | Pending | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||
| IgG4-related disease | Disease | Muhammad Zulfiqar, MD | 7/4/2025 | 10/4/2025 Emailed 9/4/2025 to remind | Pending | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||
| Unicentric Castleman disease | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Idiopathic multicentric Castleman disease | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| KSHV/HHV8-associated multicentric Castleman disease | Disease | GC | Multicentric Castleman Disease | Sudha Arumugam, MD | Complete | 01/24/2022. Emailed 5/1/2025, no response | Date completed by author: 01/24/2022 | |||||||
| B-lymphoblastic leukaemia/lymphoma | Disease | PENDING | Holli Drendel (HD) | B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified | Holli Drendel | PENDING | ||||||||
| B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy | Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG | PENDING | ||||||||
| B-lymphoblastic leukaemia/lymphoma with hypodiploidy | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy | Ashwini Yenamandra PhD FACMG Lisa Smith PhD FACMG Yassmine Akkari PhD FACMG | Complete | ||||||||
| B-lymphoblastic leukaemia/lymphoma with iAMP21 | Disease | Holli Drendel | ?Complete? Looks like tables need more editing. | HD | B-Lymphoblastic Leukemia/Lymphoma with iAMP21 [but was completed as a 5th edition page by Holli] | Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte | ?Complete | |||||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 | Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG | PENDING | ||||||||
| B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Mark G. Evans, MD, University of California, Irvine Fabiola Quintero-Rivera, MD, University of California, Irvine | Complete | ||||||||
| B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged | Yassmine Akkari Nicolas Millan | PENDING | ||||||||
| B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion | Disease | PENDING | HD | B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion | Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG Cancer Category/Type B-Lymphoblastic Leukemia/Lymphoma | PENDING | ||||||||
| B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features | Disease | Lei Zhang and Michelle Fan (trainee) | 8/8/2024 | Pending | HD | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
| B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1 | Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO | PENDING | ||||||||
| B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3 | Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO | PENDING | ||||||||
| B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion | Disease | Aiko Otsubo | 6/25/2024 | Pending | HD | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
| B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations | Disease | Lei Zhang and Michelle Fan (trainee) | 8/8/2024 | Pending | HD | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
| B-lymphoblastic leukaemia/lymphoma, NOS | Disease | HD | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| RESOLVE 4th edition ALL-Related NON-WHO entities content | B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11) | ISSUE- FIX
|
ISSUE - FIX | |||||||||||
| Monoclonal B-cell lymphocytosis | Disease | PENDING; Shashirekha Shetty | 9/4/2025 sent E-mail reminder | Shivani Golem (SG) | Monoclonal B-cell Lymphocytosis | Tsigab Bahta Hagos (trainee) / Shashirekha Shetty | PENDING, 4/30/2024 | Assigned 12/19/2022 with completion date of 1/19/2023 | ||||||
| Chronic lymphocytic leukaemia/small lymphocytic lymphoma | Disease | Jaime Nagy, PhD, University of Iowa
Renee Eigsti, MD, Pathology Services of Kalamazoo Honey Reddi, PhD, Belay Diagnostics |
Complete | SG | Already converted to 5th edition | Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD | ||||||||
| Hairy cell leukaemia | Disease | Michael Lack, MD, KUMC (trainee)/Shivani Golem | 7/16/24 | 9/4/2025 sent E-mail reminder | PENDING | SG | Need new author to update latest content. Prior author cannot update the page. | Hairy Cell Leukemia | Snehal Patel, MD, PhD | Pending WHO 5th e. July 2024 | ||||
| Splenic marginal zone lymphoma | Disease | Madhu Pantrangi | 4/15/25 | 9/4/2025 sent E-mail reminder | SG | Need new author to update latest content. Prior author cannot update the page. | Splenic Marginal Zone Lymphoma | Snehal Patel, MD, PhD | Complete | |||||
| Splenic diffuse red pulp small B-cell lymphoma | Disease | SG | Need new author to update latest content. Prior author cannot update the page. | Splenic Diffuse Red Pulp Small B-cell Lymphoma | Snehal Patel, MD, PhD | Complete | ||||||||
| Splenic B-cell lymphoma/leukaemia with prominent nucleoli | Disease | SG | Need new author to update latest content. Prior author cannot update the page. | Hairy Cell Leukemia Variant | Snehal Patel, MD, PhD | Complete | ||||||||
| Lymphoplasmacytic lymphoma | Disease | Sent e-mail to prev authors no reply | SG | Email sent to request to update 2024 | (1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia | (1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) | Complete | 4/12/2023 by FQR | ||||||
| Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue | Disease | Sent e-mail to prev authors no reply | SG | Email sent to request to update 2024 | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) | Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
Department of Pathology and Laboratory Medicine and *Pediatrics, School of Medicine, University of California Irvine (UCI) |
Complete | 4/12/23 by FQR | ||||||
| Primary cutaneous marginal zone lymphoma | Disease | Molly Walkenhorst | 9/4/2025 sent E-mail reminder | SG | NEW (No Prior) | Molly Walkenhorst, DO and Shivani Golem, PhD, FACMG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| Nodal marginal zone lymphoma | Disease | Andrew Ly | 9/4/2025 sent E-mail reminder | SG | Nodal Marginal Zone Lymphoma | Andrew Ly, DO and Shivani Golem, PhD, FACMG | Complete | 5/28/2021 | ||||||
| Paediatric nodal marginal zone lymphoma | Disease | SG | Need new author to update latest content. Prior authors cannot update the page. | Paediatric Nodal Marginal Zone Lymphoma | * Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD | Complete; Need new author to update latest content. Primary author cannot update the page. | 11/11/2020 | |||||||
| In situ follicular B-cell neoplasm | Disease | Rachel D. Burnside, PhD, MBA, FACMGG | 7/28/2023 | 9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | Pending | SG | In Situ Follicular Neoplasia | Rachel D. Burnside, PhD, MBA, FACMGG | Pending | |||||
| Follicular lymphoma | Disease | Rachel D. Burnside, PhD, MBA, FACMGG | 7/28/2023 | 9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | Pending | SG | Author also needs to correlate with 4th edition disease "Testicular Follicular Lymphoma", which is no longer a separate entity | (1) Follicular Lymphoma + (2) Testicular Follicular Lymphoma | (1 and 2) Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital Rachel D. Burnside, PhD, MBA, FACMG, University of Florida | Pending | ||||
| Paediatric-type follicular lymphoma | Disease | Rachel D. Burnside, PhD, MBA, FACMGG | 9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | SG | Need new author to update latest content. Prior authors cannot update the page. | Paediatric-Type Follicular Lymphoma | *Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG | Complete; Need new author to update latest content. Primary author cannot update the page. | 8/16/2020 | |||||
| Duodenal-type follicular lymphoma | Disease | Rachel D. Burnside, PhD, MBA, FACMGG | 7/28/2023 | 9/4/2025 sent email reminder; Last E-mail to Dr. Burnside no reply 7/17/ | Pending | SG | Duodenal-Type Follicular Lymphoma | No prior content | ||||||
| Primary cutaneous follicle centre lymphoma | Disease | Linlin Gao | 9/4/2025 Sent E-mail to remind | SG | Primary Cutaneous Follicle Centre Lymphoma | Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG | Complete | 09/10/2022 | ||||||
| In situ mantle cell neoplasm | Disease | SG | In Situ Mantle Cell Neoplasia | Rina Kansal, MD; Versiti Blood Center of Wisconsin | Complete | 7/26/2022 | ||||||||
| Mantle cell lymphoma | Disease | PENDING | 9/4/2025 set E-mail reminder | SG | Mantle Cell Lymphoma | Mahsa Khanlari, MD and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas | Pending | Target completion date 8/15/20 | ||||||
| Leukaemic non-nodal mantle cell lymphoma | Disease | Farhan Sami | 9/4/2025 sent E-mail reminder | SG | NEW (No Prior) | Farhan Sami, MD and Shivani Golem, PhD, FACMG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| Transformations of indolent B-cell lymphomas | Disease | Farhan Sami | 9/4/2025 sent E-mail reminder | SG | Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation | NEW (No Prior) | Farhan Sami, MD and Shivani Golem, PhD, FACMG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
| Diffuse large B-cell lymphoma, NOS | Disease | GC | Diffuse Large B-cell Lymphoma, Not Otherwise Specified | Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | Pending | Requested to update 14022022 | ||||||||
| T-cell/histiocyte-rich large B-cell lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements | Disease | Kate Berry, MBBS, BBus (Hons), Pathology Queensland | 5/6/2025 | 8/6/2025 Emailed 9/4/2025 to remind | GC | High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | Kate Berry, MBBS, BBus (Hons), Pathology Queensland | Complete | 24/02/2022 | |||||
| ALK-positive large B-cell lymphoma | Disease | GC | ALK-Positive Large B-cell Lymphoma | Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | |||||||||
| Large B-cell lymphoma with IRF4 rearrangement | Disease | GC | Large B-cell Lymphoma with IRF4 Rearrangement | Afia Hasnain, MBBS, PhD | Complete | 5/26/2021. Emailed 5/7//2025, no reply | ||||||||
| High grade B-cell lymphoma with 11q aberrations | Disease | GC | Burkitt-Like Lymphoma with 11q Aberration | Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | Complete | 27/01/2022 Emailed 5/7//2025, no reply | ||||||||
| Lymphomatoid granulomatosis | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| EBV-positive diffuse large B-cell lymphoma | Disease | Fnu Monika (trainee) + Andrew Siref as mentor | 3/22/24 | Pending | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
| Diffuse large B-cell lymphoma associated with chronic inflammation | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| Fibrin-associated large B-cell lymphoma | Disease | GC | Note: previously a subset DLBCL assoc with chronic inflam | Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||||
| Fluid overload-associated large B-cell lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Plasmablastic lymphoma | Disease | GC | Plasmablastic Lymphoma | Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | Complete | 28/03/2022 | ||||||||
| Primary large B-cell lymphoma of immune-privileged sites | Disease | Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | 6/28/2025 | 9/28/2025 Emailed 9/4/2025 to remind. | GC | (1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | (1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | (1) Pending + (2) Complete | (1) Not ready + (2) 03/28/22 | For "Diffuse Large B-cell Lymphoma, Not Otherwise Specified" page from Ash, Greg requested to update 14022022 | ||||
| Primary cutaneous diffuse large B-cell lymphoma, leg type | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Intravascular large B-cell lymphoma | Disease | Kate Berry, MBBS, BBus (Hons), Pathology Queensland | 5/6/2025 | 8/6/2025 Emailed 9/4/2025 to remind | GC | Intravascular Large B-cell Lymphoma | Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | Complete | 9/1/22 | Emailed 28/3/2022 for progress update | ||||
| Primary mediastinal large B-cell lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Mediastinal grey zone lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| High-grade B-cell lymphoma, NOS | Disease | GC | High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | Aiko Otsubo, PhD, Indiana University, Holli Drendel | Complete | 16/11/2021 Emailed 5/6/2025, no reply | ||||||||
| Burkitt lymphoma | Disease | GC | Burkitt Lymphoma | Becky Leung, MBBS (Hons), BSc, Pathology Queensland | Complete | 28/06/2021 Emailed 5/6/2025, no reply | ||||||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| Primary effusion lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| KSHV/HHV8-positive diffuse large B-cell lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| KSHV/HHV8-positive germinotropic lymphoproliferative disorder | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Hyperplasias arising in immune deficiency/dysregulation | Disease | FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content. What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page. | GC | |||||||||||
| Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation | Disease | FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders.
Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)" |
GC | Polymorphic Post-Transplant Lymphoproliferative Disorders | Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI) | Completed | 26/4/2022 | |||||||
| EBV-positive mucocutaneous ulcer | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Lymphomas arising in immune deficiency / dysregulation | Disease | FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others" | GC | |||||||||||
| Inborn error of immunity-associated lymphoid proliferations and lymphomas | Disease | FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5. | GC | |||||||||||
| Classic Hodgkin lymphoma | Disease | Xiaolin Hu | 5/7/2025 | 8/7/2025 Reminder email sent 9/4/2025 | GC | Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | (1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | (1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez | Pending + Completed (03/21/22) | Not completed for checking (1, 3 and 4) + 03/21/22 (2) | ||||
| Nodular lymphocyte predominant Hodgkin lymphoma | Disease | Muhammad Zulfiqar, MD | 7/4/2025 | 10/4/2025 Reminder email sent 9/4/2025 | Pending | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| Cold agglutinin disease | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| IgM monoclonal gammopathy of undetermined significance | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Non-IgM monoclonal gammopathy of undetermined significance | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Monoclonal gammopathy of renal significance | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Immunoglobulin-related (AL) amyloidosis | Disease | SG | Primary Amyloidosis | Heather E. Williams, PhD, MS, PgD, ErCLG | ?PENDING |
|||||||||
| Monoclonal immunoglobulin deposition disease | Disease | SG | Light Chain and Heavy Chain Deposition Disease | Chen Yang, MD, PhD, University of Michigan | Complete | 10/15/2022 | ||||||||
| Mu heavy chain disease | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Gamma heavy chain disease | Disease | SG | Gamma Heavy Chain Disease | Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA | Complete | 5/26/2021 | ||||||||
| Alpha heavy chain disease | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Plasmacytoma | Disease | SG | author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga) | NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| Plasma cell myeloma / multiple myeloma | Disease | Huan Mo and Zhenya Tang | 4/14/25 | 7/14/25
9/4/2025 Sent E-mail reminder to Dr. Tang |
Pending | SG | Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | (1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | (1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG | Pending | ||||
| Plasma cell neoplasms with associated paraneoplastic syndrome | Disease | PENDING | 9/4/2025 E-mail sent to Dr. Senaratne | SG | Note: author needs to include POEMS, TEMPI, and look for AESOP content | (1) POEMS Syndrome + (2) TEMPI Syndrome | (1 and 2) Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD | ?PENDING | ||||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parenthesis) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition) (Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition) (Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Kikuchi-Fujimoto disease | Disease | Sumi Kitahara (SK) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Autoimmune lymphoproliferative syndrome | Disease | Aviv Oren, MD (trainee), Karin Miller, MD | 3/25/2024 | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||
| Indolent T-lymphoblastic proliferation | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| T-lymphoblastic leukaemia / lymphoma, NOS | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Early T-precursor lymphoblastic leukaemia / lymphoma | Disease | Fei Yang, MD | Pending | SK | Early T-Cell Precursor Lymphoblastic Leukemia | Fei Yang, MD, FACMG, Kaiser Permanente Northwest | Pending | |||||||
| T-prolymphocytic leukaemia | Disease | Parastou Tizro, MD (trainee); Celeste Eno, PhD | 3/17/2024 | Complete | 6/24/2024 | SK | 7/1/2024 | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| T-large granular lymphocytic leukaemia | Disease | Nicolas LaScala (trainee); Michelle Don, MD, MS | 3/17/2024 (trainee name added on 9/9/24 by JH) | 6/30/24 | Pending | SK | T-cell Large Granular Lymphocytic Leukemia | Michelle Don, MD, MS | Pending | |||||
| NK-large granular lymphocytic leukaemia | Disease | Hailee St. Louis (trainee);
Michelle Don, MD, MS |
3/17/2024 | 6/30/24 | Pending | SK | Chronic Lymphoproliferative Disorder of NK Cells | Michelle Don, MD | Pending | |||||
| Adult T-cell leukaemia/lymphoma | Disease | SK | Adult T-cell Leukemia/Lymphoma | Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | ?Pending | |||||||||
| Sezary syndrome | Disease | Daynna J. Wolff, PhD | 3/22/2024 | SK | Sézary Syndrome | Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | Pending | |||||||
| Aggressive NK-cell leukaemia | Disease | Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD | 7/1/2024 | 8/31/2024 | Pending | SK | Aggressive NK-cell Leukemia | Shanelle De Lancy, MD, Shashirekha Shetty, PhD | ?Pending | |||||
| Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder | Disease | Amanda Xu, MD/MSc, Teodora Popa (resident) | 3/19/2024 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
| Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder | Disease | Ahmed Eladely (trainee),
Andrew Siref, MD |
4/12/2024 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
| Mycosis fungoides | Disease | Daynna J. Wolff, PhD | 3/22/2024 | SK | Mycosis Fungoides | Jane Scribner, MD and Daynna J. Wolff, PhD | Pending | |||||||
| Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis | Disease | Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD | 7/1/2024 | 8/31/224 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||
| Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma | Disease | Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD | 7/1/2024 | 8/31/2024 | Pending | SK | Primary Cutaneous Anaplastic Large Cell Lymphoma | Theresa Spivey, MD, Shashirekha Shetty, PhD | Pending | |||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| Subcutaneous panniculitis-like T-cell lymphoma | Disease | Raniah Alamri (Hemepath trainee) | 3/19/2024 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
| Primary cutaneous gamma/delta T-cell lymphoma | Disease | Mahzad Azimpouran (trainee); Sumire Kitahara, MD | 6/30/2024 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
| Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma | Disease | Ahmed Eladely (trainee),
Andrew Siref, MD |
4/12/2024 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
| Primary cutaneous peripheral T-cell lymphoma, NOS | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Indolent T-cell lymphoma of the gastrointestinal tract | Disease | SK | Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract | Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | Pending | |||||||||
| Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Enteropathy-associated T-cell lymphoma | Disease | Fnu Monika, MBBS (trainee),
Andrew Siref, MD |
3/20/2024 | Pending | SK | Enteropathy-Associated T-cell Lymphoma | *Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD | Complete | 1/21/2021 | |||||
| Monomorphic epitheliotropic intestinal T-cell lymphoma | Disease | Fnu Monika, MBBS (trainee),
Andrew Siref, MD |
3/20/2024 | Pending | SK | Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | Pending | ||||||
| Intestinal T-cell lymphoma, NOS | Disease | SK | Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) | Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) | Complete | 9/26/2022 | ||||||||
| Hepatosplenic T-cell lymphoma | Disease | Forough Sargolzaeiaval (trainee);
Michelle Don, MD, MS |
3/19/2024 | 6/30/24 | Complete | 5/13/24 | SK | 10/18/24 | Hepatosplenic T-cell Lymphoma | Michelle Don, MD, MS | Complete | 1/21/2021 | ||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| ALK-positive anaplastic large cell lymphoma | Disease | Miguel Gonzalez Mancera, MD (trainee)
Sumire Kitahara, MD |
6/6/24 | Pending | SK | Anaplastic Large Cell Lymphoma, ALK-Positive | Miguel Gonzalez Mancera, MD
Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA |
Complete | 09/23/2022 | |||||
| ALK-negative anaplastic large cell lymphoma | Disease | Miguel Gonzalez Mancera, MD (trainee)
Sumire Kitahara, MD |
6/6/24 | Pending | SK | Anaplastic Large Cell Lymphoma, ALK-Negative | Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA | Complete | 09/23/2022 | |||||
| Breast implant-associated anaplastic large cell lymphoma | Disease | Lynne Abruzzo, MD, PhD | 4/1/2024 | Pending | SK | Breast Implant-Associated Anaplastic Large Cell Lymphoma | Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | Pending | ||||||
| Nodal TFH cell lymphoma, angioimmunoblastic-type | Disease | Rachel Burnside, PhD | 7/28/2023 | Pending | SK | prior authors not available | Angioimmunoblastic T-cell Lymphoma | Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG | Pending | |||||
| Nodal TFH cell lymphoma, follicular-type | Disease | Rachel Burnside, PhD | 7/28/2023 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
| Nodal TFH cell lymphoma, NOS | Disease | SK | Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype | Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | Pending | |||||||||
| Peripheral T-cell lymphoma, NOS | Disease | Bo Hong, MD | 6/25/2023 | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||
| EBV-positive nodal T- and NK-cell lymphoma | Disease | Fnu Monika, MBBS (trainee), Andrew Siref, MD | 3/22/2024 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
| Extranodal NK/T-cell lymphoma | Disease | Amanda Xu, MD/MSc, Teodora Popa (resident) | 3/19/2024 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
| Severe mosquito bite allergy | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| Hydroa vacciniforme lymphoproliferative disorder | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Systemic chronic active EBV disease | Disease | Karin Miller, MD | 3/25/2024 | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||
| Systemic EBV-positive T-cell lymphoma of childhood | Disease | Karin Miller, MD | 3/25/2024 | SK | prior authors not available | Systemic EBV-Positive T-cell Lymphoma of Childhood | Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA | Complete | 11/21/2021 | |||||
CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Follicular dendritic cell sarcoma | Disease | GC | Follicular Dendritic Cell Sarcoma | Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG | ?Pending | |||||||||
| EBV-positive inflammatory follicular dendritic cell sarcoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Fibroblastic reticular cell tumour | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Intranodal palisaded myofibroblastoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
| Littoral cell angioma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Splenic hamartoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
| Sclerosing angiomatoid nodular transformation (SANT) of spleen | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
CHAPTER 7 (GENETIC TUMOUR SYNDROMES) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fanconi anaemia | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) |
| Bloom syndrome | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) |
| Ataxia-telangiectasia syndrome | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) |
| RASopathies | Disease | NA | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) |